Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05058950 · ClinicalTrials.gov registry record
An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 22,720
- Enrollment target
NCT05058950: Clinical Trial study, sponsored by Biogen.
NCT05058950 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 22,720 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05058950 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 22,720 participants
- Enrollment target
Study Summary
The primary objectives are to develop and validate a classifier using multimodal passive sensor data and metrics derived from normal iPhone and Apple Watch usage to distinguish individuals with normal cognition from those with mild cognitive impairment (MCI) and to develop and validate a cognitive wellness score that tracks fluctuations in cognitive performance over time using multimodal passive sensor data and metrics derived from normal iPhone and Apple Watch usage.
Primary Outcome
A classifier is a mathematical function that uses collected data to calculate the probability that an individual belongs in a given category. The reference standard for the classifier is clinical diagnosis of MCI in normal clinical care or in a research cohort.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,720 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2023-09-19 |
Why NCT05058950 stopped before completion
NCT05058950 is an observational study that tracks outcomes without assigning an intervention. Its 22,720 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05058950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05058950 about?
NCT05058950 is a clinical study titled "An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging". The primary objectives are to develop and validate a classifier using multimodal passive sensor data and metrics derived from normal iPhone and Apple Watch usage to distinguish individuals with normal cognition from those with mild cognitive impairment (MCI) and to develop and validate a cognitive w...
What is the current status of trial NCT05058950?
This trial is currently terminated. The enrollment target is 22,720 participants. The study started on 2021-09-20. Estimated completion is 2023-09-19.
Who is sponsoring clinical trial NCT05058950?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI